Remedica Limited has initiated a voluntary recall of specific batches of Remethan 100mg Prolonged-Release Tablets as part of precautionary measures linked to out-of-specification findings in product stability studies.
In a statement, the company clarified that the recall is purely preventive and that there is currently no cause for concern among patients using the medication.
Nevertheless, patients taking the product are advised to contact their treating physician or pharmacist to receive guidance on continuing their treatment with available alternative medicines.
Remethan 100mg is a prescription-only non-steroidal anti-inflammatory drug (NSAID) used to treat pain, inflammation and swelling associated with conditions affecting the joints, muscles and tendons, including tendinitis, rheumatoid arthritis, fractures and dislocations.
It is also used to relieve pain and inflammation following dental procedures and minor surgical operations.
The recalled batches carry expiry dates ranging from September 2026 to November 2030.
According to Remedica, only batches 116856, 122934 and 127806 are likely to remain available in circulation.
The company said that further announcements or additional measures may follow if new information emerges from the ongoing investigation.
Remedica reiterated that protecting patient health and safety remains its highest priority.
Source: CNA
